Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study
Konrad Reinhart(Humboldt-Universität zu Berlin), Martin Kaul, Klaus Tschaikowsky, J. Kempeni, Stuart Withington, Bengt Gårdlund, Rainer Brase(Apple (Israel)), Mark Smithes, Pierre Damas, José M. Tellado, Juergen Eiselstein, Reuven Zimlichman(Tel Aviv University), T. Menges, H. Küpper, Jean‐Louis Vincent(Université Libre de Bruxelles), Jan H. Zwaveling, Antonio Salgado-Remigio
Cited by 261
Related Papers
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
|JAMA|2016|28.1k
The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure
|Intensive Care Medicine|1996|11.7k
Surviving Sepsis Campaign
|Critical Care Medicine|2013|9.7k
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012
|Intensive Care Medicine|2013|7.3k
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
|New England Journal of Medicine|2001|6.1k